Company family · HQ CY
Medochemie: medicine shortages
As of 2 Nov 2026, 56 Medochemie products have a reported shortage across 2 countries, covering 14 medicines.
Where
Which therapeutic classes
Why, compared with all companies
Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.
Latest changes
All changesNo changes recorded yet. Changes are tracked from our daily snapshots.
Open shortages over time
Products short per day in the 5 countries tracked since 31 Oct 2026, from our daily snapshots. The history lengthens every day.
When its current shortages began
Against its peers
Breadth vs depth
Further right: more products short. Higher: more different medicines affected.
Medicines short
Download CSV| Medicine | Where this company is short | Products | Earliest start | Main reason | Short anywhere |
|---|---|---|---|---|---|
| Solifenacin | 10 | 29 Nov 2024 | Commercial decision or withdrawal | 6/16 | |
| Memantine | 9 | 1 Oct 2024 | Commercial decision or withdrawal | 8/16 | |
| Aripiprazole | 8 | 15 Aug 2025 | Commercial decision or withdrawal | 9/16 | |
| Pregabalin | 7 | 16 Jun 2025 | Commercial decision or withdrawal | 11/16 | |
| Rosuvastatin | 7 | 31 Dec 2025 | Commercial decision or withdrawal | 12/16 | |
| Lacosamide | 5 | 30 Jan 2026 | Commercial decision or withdrawal | 6/16 | |
| Diclofenac | 2 | 30 Oct 2026 | Manufacturing problem | 3/16 | |
| Donepezil | 2 | 20 Oct 2026 | Commercial decision or withdrawal | 8/16 | |
| Cefazolin | 1 | 23 Dec 2026 | Manufacturing problem | 4/16 | |
| Cefotaxime | 1 | 1 Dec 2026 | Manufacturing problem | 7/16 | |
| Irbesartan | 1 | 4 Sep 2026 | Commercial decision or withdrawal | 6/16 | |
| Palonosetron | 1 | 22 Oct 2026 | Not stated | 5/16 | |
| Ticagrelor | 1 | 1 Feb 2027 | Commercial decision or withdrawal | 2/16 | |
| Tranexamic Acid | 1 | 23 May 2024 | Not stated | 10/16 |
Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.